Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs.

This research paper focuses on the complexity of advanced therapy medicinal products (ATMPs) clinical trials. It explores the various challenges faced by academic hospitals—usually the centers for these trials—due to an increase in public demand, competition, and costs. The research also highlights the necessity for appropriate infrastructure, expertise, and standardized training for performing such trials.

Advanced Therapy Medicinal Products (ATMPs) and Clinical Trials

• In the field of drug development, ATMPs represent a completely different sphere engaging more with academia. These are innovative therapies often involving genes or cells that hold potential to revolutionize disease treatment.
• Clinical trials for ATMPs are usually conducted in academic hospitals. The settings range from early tests led by academics to full-fledged, industry-funded trials aimed at achieving market authorization.
• Recent breakthroughs in some ATMPs—specifically genetically engineered immune cells—have put academic hospitals in the spotlight, leading to heightened public interest, amplified competitive tension and increased costs.

Challenges and Required Parameters

• Despite the above, introducing advances like these can bring certain risks and toxicities. To effectively navigate these, appropriate infrastructure and expertise are crucial.
• Moreover, given the novelty and complexity of these therapies, standardized training is a paramount need to mitigate potential errors or complications during the course of clinical trials. However, the standardization process is not yet fully completed.

Ethics Committees and Qualification Criteria

• Considering the factors discussed, the paper ponder on how Ethics Committees, that supervise the conduct of clinical trials, can consider trial sites and investigators as qualified for ATMP trials.
• This vital issue of qualification draws attention to the importance of a strong, consistent evaluation metric for academic hospitals and investigators involved in ATMP clinical trials to ensure patient safety and overall efficacy of the study.